i
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
-
Jan 26 2018
Source: MMWR Morb Mortal Wkly Rep. 67(3):103-108. -
Alternative Title:MMWR Morb Mortal Wkly Rep
-
Publisher's site:
-
Personal Author:
-
Corporate Authors:
-
Description:On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01|), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.
Published also as: Am J Transplant. 2018 Mar;18(3):756-762. doi: 10.1111/ajt.14683. (PMID: 29462512).
-
Subject:
-
Source:
-
Pubmed ID:29370152
-
Pubmed Central ID:PMC5812314
-
Document Type:
-
Name as Subject:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
[PDF-114.29 KB]
Email
CDC-INFO
